Literature DB >> 28911860

Glucose elicits serine/threonine kinase VRK1 to phosphorylate nuclear pregnane X receptor as a novel hepatic gluconeogenic signal.

Saki Gotoh1, Yuu Miyauchi1, Rick Moore1, Masahiko Negishi2.   

Abstract

Low glucose stimulated phosphorylation of pregnane X receptor (PXR) at Ser350 in correlation with an increased gluconeogenesis in human hepatoma-derived HepG2 cells. Only glucose, but neither insulin nor glucagon, stimulated this phosphorylation. Here, serine/threonine kinase, vaccinia related kinase 1 (VRK1)-mediated phosphorylation of PXR is now defined as this glucose-elicited novel signal. In low glucose conditions, VRK1 directly phosphorylates PXR at Ser350, enabling PO3-PXR to scaffold protein phosphatase PP2Cα. This PP2Cα dephosphorylates serine/threonine kinase 2 (SGK2) at Thr193. This dephosphorylation dissociates SGK2 from and actives the phosphoenolpyruvate carboxykinase 1 (PCK1) gene as phosphorylated SGK2 binds and represses the gene. Conversely, VRK1 self-represses its activity to phosphorylate PXR through cyclin-dependent kinase 2 (CDK2) in high glucose conditions, resulting in the repression of the PCK1 gene. This PXR phosphorylation was also observed in fasting mouse livers. Thus, the VRK1-CDK2-PXR-PP2Cα-SGK2 pathway can be a novel physiological cell signaling that regulates gluconeogenesis in response to glucose.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  CDK2; Glucose; Hepatic gluconeogenesis; PXR; SGK2; VRK1

Mesh:

Substances:

Year:  2017        PMID: 28911860     DOI: 10.1016/j.cellsig.2017.09.003

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  9 in total

1.  Mice blocking Ser347 phosphorylation of pregnane x receptor develop hepatic fasting-induced steatosis and hypertriglyceridemia.

Authors:  Kosuke Yokobori; Artiom Gruzdev; Masahiko Negishi
Journal:  Biochem Biophys Res Commun       Date:  2022-05-18       Impact factor: 3.322

Review 2.  The Roles of Xenobiotic Receptors: Beyond Chemical Disposition.

Authors:  Bryan Mackowiak; Jessica Hodge; Sydney Stern; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2018-05-14       Impact factor: 3.922

Review 3.  Nuclear receptor phosphorylation in xenobiotic signal transduction.

Authors:  Masahiko Negishi; Kaoru Kobayashi; Tsutomu Sakuma; Tatsuya Sueyoshi
Journal:  J Biol Chem       Date:  2020-08-11       Impact factor: 5.157

4.  MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor.

Authors:  Jiaqi Li; Jing Zhao; Huan Wang; Xiaohan Li; Aixia Liu; Qin Qin; Boan Li
Journal:  Onco Targets Ther       Date:  2018-09-17       Impact factor: 4.147

5.  Nutritional status modifies pregnane X receptor regulated transcriptome.

Authors:  Fatemeh Hassani-Nezhad-Gashti; Outi Kummu; Mikko Karpale; Jaana Rysä; Jukka Hakkola
Journal:  Sci Rep       Date:  2019-11-13       Impact factor: 4.379

Review 6.  PXR and 4β-Hydroxycholesterol Axis and the Components of Metabolic Syndrome.

Authors:  Janne Hukkanen; Jukka Hakkola
Journal:  Cells       Date:  2020-11-09       Impact factor: 6.600

7.  RORα phosphorylation by casein kinase 1α as glucose signal to regulate estrogen sulfation in human liver cells.

Authors:  Hao Hu; Masahiko Negishi
Journal:  Biochem J       Date:  2020-09-30       Impact factor: 3.857

Review 8.  The Interface between Cell Signaling Pathways and Pregnane X Receptor.

Authors:  Robert S Rogers; Annemarie Parker; Phill D Vainer; Elijah Elliott; Dakota Sudbeck; Kaushal Parimi; Venkata P Peddada; Parker G Howe; Nick D'Ambrosio; Gregory Ruddy; Kaitlin Stackable; Megan Carney; Lauren Martin; Thomas Osterholt; Jeff L Staudinger
Journal:  Cells       Date:  2021-11-22       Impact factor: 6.600

9.  Phosphorylation of vaccinia-related kinase 1 at threonine 386 transduces glucose stress signal in human liver cells.

Authors:  Kosuke Yokobori; Yuu Miyauchi; Jason G Williams; Masahiko Negishi
Journal:  Biosci Rep       Date:  2020-04-30       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.